Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Phase III Randomized Study of Imatinib Therapy in Chronic Phase Chronic Myeloid Leukemia Comparing Standard Dose-Escalation with Progressive Dose-Escalation (JALSG CML207 study)

Koichi Miyamura, MD PhD, Shigeki Ohtake, MD PhD, Kazunori Ohnishi, MD PhD, Noriko Usui, MD PhD, Chiaki Nakaseko, MD PhD, Hiroyuki Fujita, MD PhD, Shin Fujisawa, MD PhD, Toru Sakura, MD, Hirokazu Okumura, Yoshihiro Hatta, MD PhD, Nobuhiko Emi, MD PhD, Tomoki Naoe, MD PhD

Blood (2016) 128 (22): 941.

https://doi.org/10.1182/blood.V128.22.941.941

Published: 2016

Journal Articles

Phase 1 Clinical Trial of Adoptive Immunotherapy for Acute Myelogenous Leukemia and Myelodysplastic Syndrome, Using Gene-Modified Autologous Lymphocytes Expressing WT1-Specific T-Cell Receptor

Kazushi Tanimoto, MD PhD, Hiroshi Fujiwara, MD PhD, Isao Tawara, MD PhD, Masahiro Masuya, MD PhD, Shinichi Kageyama, MD PhD, Tetsuya Nishida, MD PhD, Makoto Murata, MD PhD, Seitaro Terakura, MD PhD, Yoshiki Akatsuka, MD PhD, Hiroaki Ikeda, MD PhD, Yoshihiro Miyahara, MD PhD, Ikuei Nukaya, PhD, Kazutoh Takesako, PhD, Nobuhiko Emi, MD PhD, Naoyuki Katayama, MD PhD, Hiroshi Shiku, MD PhD, Masaki Yasukawa, MD PhD

Blood (2016) 128 (22): 1653.

https://doi.org/10.1182/blood.V128.22.1653.1653

Published: 2016

Journal Articles

Construction and Molecular Characterization Of a T-Cell Receptor-Like Antibody and CAR-T Cells Specific For Minor Histocompatibility Antigen HA-1H

Yoko Inaguma, MD, Yasushi Akahori, PhD, Yoshiki Akatsuka, MD, PhD, Yuko Murayama, Keiko Shiraishi, Sachiko Tsuzuki-Iba, Akemi Endoh, Juri Tsujikawa, Ayako Demachi-Okamura, PhD, Kaho Hiramatsu, Hiroh Saji, PhD, Yukiya Yamamoto, MD, PhD, Naoki Yamamoto, PhD, Nishimura Yasuharu, MD, PhD, Toshitada Takahashi, MD, PhD, Kiyotaka Kuzushima, MD, PhD, Nobuhiko Emi, MD, PhD

Blood (2013) 122 (21): 4490.

https://doi.org/10.1182/blood.V122.21.4490.4490

Published: 2013

Journal Articles

WT-1 Expression Level In BM Is The Great Prognostic Marker In Three Of Classification IPSS, WPSS, and Latest Revised IPSS(IPSS-R)

Sumiko Kobayashi, MD, PhD, Yasunori Ueda, MD, PhD, Mineo Kurokawa, MD, PhD, Kiyoyuki Ogata, MD, PhD, Hirohiko Shibayama, Nobuhiko Emi, MD, PhD, Kensuke Usuki, MD, PhD, Kazuma Ohyashiki, MD, PhD, Keiya Ozawa, MD, PhD, Yasushi Miyazaki, MD, PhD, Akira Matsuda, MD, PhD, Kaoru Tohyama, MD, PhD, Kinuko Mitani, M.D., Ph.D., Tomoki Naoe, MD, PhD, Haruo Sugiyama, MD, PhD

Blood (2013) 122 (21): 2795.

https://doi.org/10.1182/blood.V122.21.2795.2795

Published: 2013

Journal Articles

Long-Term Outcome Of Acute Promyelocytic Leukemia (APL) With Lower Initial Leukocyte Counts By Using All- Trans Retinoic Acid (ATRA) Alone For Remission Induction Therapy: Japan Adult Leukemia Study Group (JALSG) APL97 Study

Takaaki Ono, MD, PhD, Akihiro Takeshita, MD, PhD, Katsuji Shinagawa, MD, PhD, Yuji Kishimoto, MD, PhD, Hitoshi Kiyoi, MD, PhD, Masaya Okada, MD, PhD, Takahiro Yamauchi, MD, PhD, Nobuhiko Emi, MD, PhD, Hiroyuki Fujita, MD, Mitsuhiro Matsuda, MD, PhD, Fumihiko Monma, MD, PhD, Shigeki Ohtake, MD, PhD, Chiaki Nakaseko, M.D., Ph.D., Masatomo Takahashi, MD, PhD, Yukihiko Kimura, MD, PhD, Masako Iwanaga, MD, PhD, MPH, Norio Asou, MD, PhD, Tomoki Naoe, MD, PhD

Blood (2013) 122 (21): 3950.

https://doi.org/10.1182/blood.V122.21.3950.3950

Published: 2013

Journal Articles

CD7 Expression On Blasts Of Myelodysplastic Syndromes Is Associated With Apoptosis Resistance With Decreased Expression Of The Proapoptotic Protein Bad and An Independent Unfavorable Prognostic Factor Together With The Revised IPSS Score In Patients

Yasuko Hamada, MD, Hideto Tamura, MD, PhD, Mariko Ishibashi, PhD, Namiko Okuyama, MD, Asaka Kondo, MD, PhD, Keiichi Moriya, MD, PhD, Kiyoyuki Ogata, MD, PhD, Keiji Kakumoto, Yoshihide Miyazaki, Akira Matsuda, MD, PhD, Kaoru Tohyama, MD, PhD, Yasunori Ueda, MD, PhD, Mineo Kurokawa, MD, PhD, Hirohiko Shibayama, Nobuhiko Emi, MD, PhD, Kinuko Mitani, M.D., Ph.D., Tomoki Naoe, MD, PhD, Haruo Sugiyama, MD, PhD, Koiti Inokuchi, MD, PhD

Blood (2013) 122 (21): 2799.

https://doi.org/10.1182/blood.V122.21.2799.2799

Published: 2013

Journal Articles

Serum α1-Acid Glycoprotein Level Associate with Imatinib Trough Plasma Concentration and Clinical Outcome in CML Patients Treated with Imatinib: Blood Level Testing of Imatinib in Nagoya (BINGO) Study.

Yuichi Ishikawa, MD, PhD, Hitoshi Kiyoi, MD, PhD, Keisuke Watanabe, MD, Yasuyuki Nakano, MD, PhD, Kunio Kitamura, MD, PhD, Akio Kohno, MD, PhD, Toshiya Yokozawa, MD, PhD, Isamu Sugiura, MD, PhD, Akitoshi Hanamura, MD, PhD, Hiroatsu Iida, MD, PhD, Kazuhito Yamamoto, MD, PhD, Ritsuro Suzuki, MD, PhD, Koichi Miyamura, MD, PhD, Nobuhiko Emi, MD, PhD, Kazunori Ohnishi, MD, PhD, Tomoki Naoe, MD, PhD

Blood (2009) 114 (22): 4266.

https://doi.org/10.1182/blood.V114.22.4266.4266

Published: 2009

Journal Articles

Clinical Characteristics and Outcomes in Patients with t(8;21) Acute Myeloid Leukemia in Japan.

Hiroto Narimatsu, MD, Toshiya Yokozawa, MD, Hiroatsu Iida, MD, Motohiro Tsuzuki, MD, Masaya Hayakawa, MD, Takaaki Takeo, MD, Masaki Iino, MD, Takuji Ichihashi, MD, Chiaki Kato, MD, Akiyo Sawamoto, MD, Hiroshi Sao, MD, Masamitsu Yanada, MD, Nobuhiko Emi, MD, Hitoshi Kiyoi, MD, Tetsushi Yamaguchi, MD, Tomoki Naoe, MD, Ritsuro Suzuki, MD, Isamu Sugiura, MD

Blood (2007) 110 (11): 4269.

https://doi.org/10.1182/blood.V110.11.4269.4269

Published: 2007

Journal Articles

High Complete Remission Rate and Promising Outcome by Combination of Imatinib and Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia.

Masamitsu Yanada, MD, Jin Takeuchi, MD, Isamu Sugiura, MD, Hideki Akiyama, MD, Noriko Usui, MD, Fumiharu Yagasaki, MD, Nobuhiko Emi, MD, Yasushi Miyazaki, MD, Shigeki Ohtake, MD, Itsuro Jinnai, MD, Keitaro Matsuo, MD, Tomoki Naoe, MD, Ryuzo Ohno, MD

Blood (2005) 106 (11): 1827.

https://doi.org/10.1182/blood.V106.11.1827.1827

Published: 2005

Journal Articles

Increased Risk for Treatment-Related Mortality of Bone Marrow Transplantation in GSTM1 -Positive Recipients.

Seitaro Terakura, MD, Makoto Murata, MD, Tetsuya Nishida, MD, Nobuhiko Emi, MD, Yoshiki Akatsuka, MD, Stanley R. Riddell, MD, Yasuo Morishima, MD, Yoshihisa Kodera, MD, Tomoki Naoe, MD

Blood (2005) 106 (11): 1756.

https://doi.org/10.1182/blood.V106.11.1756.1756

Published: 2005

Journal Articles

Combination of Intensive Chemotherapy and Imatinib (IDEAMOP Regimen) for the Treatment of Newly Diagnosed BCR-ABL Positive Acute Lymphoblastic Leukemia; Excellent Efficacy without Increasing Toxicity.

Masamitsu Yanada, MD, Nobuhiko Emi, MD, Noriko Usui, MD, Jin Takeuchi, MD, Isamu Sugiura, MD, Makoto Takeuchi, MD, Tohru Kobayashi, MD, Fumiharu Yagasaki, MD, Shigeki Ohtake, MD, Keitaro Matsuo, MD, Tomoki Naoe, MD, Ryuzo Ohno, MD

Blood (2004) 104 (11): 2736.

https://doi.org/10.1182/blood.V104.11.2736.2736

Published: 2004

Journal Articles

Impact of Homozygous Deletion of UGT2B17 on Outcome of Allogeneic BMT.

Seitaro Terakura, MD, Makoto Murata, MD, PhD, Tetsuya Nishida, MD, PhD, Nobuhiko Emi, MD, PhD, Yoshiki Akatsuka, MD, PhD, Stanley R. Riddell, MD, Yasuo Morishima, MD, PhD, Yoshihisa Kodera, MD, PhD, Tomoki Naoe, MD, PhD

Blood (2004) 104 (11): 1837.

https://doi.org/10.1182/blood.V104.11.1837.1837

Published: 2004

NARROW

Phase III Randomized Study of Imatinib Therapy in Chronic Phase Chronic Myeloid Leukemia Comparing Standard Dose-Escalation with Progressive Dose-Escalation (JALSG CML207 study)

Phase 1 Clinical Trial of Adoptive Immunotherapy for Acute Myelogenous Leukemia and Myelodysplastic Syndrome, Using Gene-Modified Autologous Lymphocytes Expressing WT1-Specific T-Cell Receptor

Construction and Molecular Characterization Of a T-Cell Receptor-Like Antibody and CAR-T Cells Specific For Minor Histocompatibility Antigen HA-1H

WT-1 Expression Level In BM Is The Great Prognostic Marker In Three Of Classification IPSS, WPSS, and Latest Revised IPSS(IPSS-R)

Long-Term Outcome Of Acute Promyelocytic Leukemia (APL) With Lower Initial Leukocyte Counts By Using All- Trans Retinoic Acid (ATRA) Alone For Remission Induction Therapy: Japan Adult Leukemia Study Group (JALSG) APL97 Study

CD7 Expression On Blasts Of Myelodysplastic Syndromes Is Associated With Apoptosis Resistance With Decreased Expression Of The Proapoptotic Protein Bad and An Independent Unfavorable Prognostic Factor Together With The Revised IPSS Score In Patients

Serum α1-Acid Glycoprotein Level Associate with Imatinib Trough Plasma Concentration and Clinical Outcome in CML Patients Treated with Imatinib: Blood Level Testing of Imatinib in Nagoya (BINGO) Study.

Clinical Characteristics and Outcomes in Patients with t(8;21) Acute Myeloid Leukemia in Japan.

High Complete Remission Rate and Promising Outcome by Combination of Imatinib and Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia.

Increased Risk for Treatment-Related Mortality of Bone Marrow Transplantation in GSTM1 -Positive Recipients.

Combination of Intensive Chemotherapy and Imatinib (IDEAMOP Regimen) for the Treatment of Newly Diagnosed BCR-ABL Positive Acute Lymphoblastic Leukemia; Excellent Efficacy without Increasing Toxicity.

Impact of Homozygous Deletion of UGT2B17 on Outcome of Allogeneic BMT.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only